The Value of Trust: We support Aicarm with the 5×1000

In this tax return period, we would like to draw attention to an important opportunity: the destination of the 5x1000 to Aicarm, the Italian Cardiomyopathies Association. The 5x1000 donation allows all taxpayers to donate a portion of their taxes to a non-profit organization of their choice, without additional costs as it is already included in the amount paid.

May 26, 2024|

Dialogue between a smoker and his family doctor

Adolescents and smoking, the uncomfortable conditions when smoking is often talked about as a vice, but in reality it is an addiction. The tobacco industry exerting a strong influence on politicians, WHO data says that smoking causes around 8 million premature deaths every year. Anti-smoking centers and strategies to stop smoking and electronic cigarettes which are less harmful than traditional ones, but remain dangerous. These are the main topics of the thematic sheet on smoking created by Dr. Mauro Pecchioli, built according to the “Questions & Answers” ​​format. Below are the first seven questions. By clicking on the link at the bottom of the article you can read the other 9.

May 25, 2024|

My experience in San Diego where new therapies are explored

At the University of California San Diego (UCSD), the first gene therapy for a hereditary heart disease was developed: Danon disease, characterized by the accumulation of glycogen, due to variants in the gene that codes for a protein necessary for the elimination of cell phone waste. The type of gene therapy developed by the researchers consists of the LAMP2B gene contained in a virus capable of entering heart cells. The encouraging results of the research have allowed the experimentation to continue and a further study on male patients with Danon disease will soon begin in Europe. The only center in Italy invited to participate will be the AOU Meyer.

May 25, 2024|

Myectomy and mitral plastic surgery, the most effective therapy for young patients

The Hypertrophic Obstructive Cardiomyopathy Treatment course is designed to present the impact of obstruction on the quality of life and prognosis of patients with hypertrophic obstructive cardiomyopathy. The experiences gained so far with "classic" drugs, such as beta-blockers capable of effectively and safely reducing outflow obstruction and, in some cases, postponing or avoiding surgery, will be discussed. Over the last 2 decades, cardiac surgical experience with myectomy and mitral plasty have significantly improved patients' symptoms and their prognosis. With the introduction of Mavacamten, already available for "compassionate use" for patients over 18 years of age, and perhaps Aficamten in the future, there are prospects for long-term treatment, which currently makes it more suitable for elderly patients and in the future, perhaps, also in young patients, in whom cardiac surgery currently remains a fundamental solution.

May 25, 2024|

Gene therapy for hypertrophic cardiomyopathy, what's new

Cardiomyopathies are a group of diseases that affect the heart muscle, causing impaired function of the heart muscle and even dangerous complications. Despite the efforts of medical research, to date there is no definitive cure. Research is also focusing on gene therapies that aim to correct the genetic mutations underlying some forms of cardiomyopathy. Informing correctly on the one hand avoids generating false expectations in patients, while on the other it supports funding and efforts of the scientific community. For these reasons AICARM inaugurates a new column which will present the news and developments for the treatment of cardiomyopathies. We will present works that come from institutions and pharmaceutical companies, both Italian and foreign, always with authority and independence from the market, and in favor of patients with cardiomyopathy and their doctors.

May 18, 2024|

Risk assessment of beta-blockers in pregnant women with cardiomyopathy

Therapy during pregnancy involves the use of various drugs including the beta-blocker family, used in the treatment of some cardiomyopathies, cardiac arrhythmias and arterial hypertension. They are not responsible for an increase in the risk of birth defects, so in most cases pharmacological treatment during pregnancy is not only not contraindicated, but is absolutely recommended to maintain good clinical compensation of Cardiomyopathy, of fundamental importance for the regular progress of the pregnancy itself. In any case, management of these pregnancies by a multidisciplinary group that includes specialists in cardiology, obstetrics, obstetric ultrasound and echocardiography, perinatal toxicology, paediatrics is indicated.

April 27 2024|

Procreation and physical activity in the foreground at the course for expert patients

The Milan course for Expert Patients in Hereditary Myocardial Diseases on March 23, 2024 was well attended. Those present created an interactive and collaborative environment. The exchange of information and experiences on crucial topics such as hereditary diseases and genetic counseling, arrhythmias and drug therapy is particularly useful and appreciated. Also in the foreground are issues related to contraception and procreation, aspects of vital importance that directly involve women, families and couples

April 26 2024|

Comment on the genetic survey (published in the March 2024 Newsletter)

We publish the comment of Dr. Francesca Torricelli, geneticist and former director of the Genetic Diagnostic Unit of the Careggi University Hospital, relating to the results of the survey on the availability of genetic testing at the main Italian Medical Genetics laboratories of the NHS for patients with Cardiomyopathies published on Aicarm News of March 2024.

April 26 2024|

Davide Antoniucci: dedication to patients and innovation

The memory of Professor Franco Cecchi The Director of the Cardiology Department of the Careggi Hospital for over two decades, who passed away a few days ago, is responsible for the introduction of a new technique for the treatment of patients with acute myocardial infarction

March 21 2024|

The availability of genetic testing for cardiomyopathies in Italy

The results of a survey on the availability of genetic testing at the main Italian medical genetics laboratories of the NHS for patients with cardiomyopathies. Together with AICARM Aps, Dr. Maria Iascone (director of the Medical Genetics Laboratory of the ASTT Papa Giovanni XXIII of Bergamo) and Dr. Francesca Girolami (Cardiogenetics of the Meyer IRCCS University Hospital, of Florence). These are the most important conclusions: in most cases the test is carried out together with genetic counselling, it requires an average of 3-6 months to carry out and is always carried out with NGS technology.

March 21 2024|
Back to the top